Astrazeneca Share Discussion Threads

[alphorn] 09/11/2021 15:09

AstraZeneca commits to vaccines business with new division. Move comes despite Anglo-Swedish group’s non-profit Covid-19 jab suffering setbacks earlier this year. (FT)

[philanderer] 07/11/2021 23:53

Questor: AstraZeneca’s quality is not really in doubt, but are expectations too high?

Questor share tip: the share price is 30pc higher than when we first expressed reservations about valuation

[philanderer] 06/11/2021 00:45

Share of the week: Astrazeneca


Astrazeneca shares have been looking healthy of late, with the stock trading close to record highs as it prepares to deliver its third-quarter results next Friday.

The pharma group's share price surge over the last nine months is a vindication for boss Pascal Soriot, as well as the company's focus on its drug development pipeline.

It may also be a gesture of thanks for its contributions to the Covid-19 vaccine effort, with the firm expected to have shipped around 3bn doses of its Vaxzevria jab across the world by the end of this year.

Unlike rivals, Astra has been selling the vaccine for the same price it costs to produce, meaning the jab is losing money for the group.

As a result, analysts will instead be looking deeper into Astra's third-quarter numbers for how sales of the group's other products are coming along, particularly after it upgraded its full-year sales and earnings forecasts in July.

Full-year numbers are expected to see percentage sales growth in the low 20 per cent range, while earnings are predicted to come in at between 374p and 400p per share.

Analysts will also be keeping an eye on how the reduction in Covid-19 infections has affected demand for Astra's other products as healthcare providers begin to refocus on other ailments as the pandemic eases in multiple countries.

Of particular interest will be the firm's cancer treatments, with its Tagrisso, Imfinzi and Lynparza drugs having posted very strong sales.

[stato] 05/11/2021 12:20

Not sure why Pfizer news should have have such an impact as AZN are not for profit in the CV19 space.

[haideralifool] 05/11/2021 12:14

Nice rise in the am and then boom the Pfizer covid drug good news hits.

[gregb] 04/11/2021 12:46

Full article here:hTTps://www.moneycab.com/international/astrazeneca-zieht-gesuch-fuer-impfstoff-zulassung-in-der-schweiz-zurueck/

[alphorn] 04/11/2021 12:29

AZN has today withdrawn its drug application from SwissMedic for its vaccine. I hear very little about it even in the UK media - is it still used?

[philanderer] 02/11/2021 15:09

Best one of my lot today.

[bb123] 02/11/2021 14:29

J.P.MORGAN KEEPS ASTRAZENECA AS 'TOP PICK' ON GROWTH OUTLOOK, UNDERVALUATION


(Sharecast News) - AstraZeneca's growth outlook is the best in its sector and was not yet reflected in its share price, analysts at JP Morgan said following a 'deep dive' into the drug maker's financials.
Hence their decision to keep the shares as their 'top pick' in the sector.

In local currency terms, the broker estimated that the company's core earnings per share were set to grow by 33%, 27% and 23% between 2021-23 - excluding its Covid-19 vaccine.

Subsequently, EPS was seen growing at a compound annual rate of growth of 9% over 2023-26.

Furthermore, Astra was only trading on 14.5 times' its estimated core EPS for 2023, against its sector trading on 16.5.

Yet the expected rate of growth in the drugmaker's core EPS across 2023-26 in compound annual terms was expected to be four percentage points higher thanks to its comparatively young on-market portfolio and deep late stage pipeline.

"Given our forecast for a strong growth outlook, and the compelling valuation, we remain Overweight, with Astra remaining a top pick in the sector."

[bountyhunter] 28/10/2021 18:56

checked eurozone interest rates, no change and that was at 12:45 more than an hour before the spike

[bountyhunter] 28/10/2021 15:31

was that at 14:00? European Bank, did they raise rates?

[riskonricky] 28/10/2021 15:08

Interest rate decision?

[bountyhunter] 28/10/2021 14:34

what's spiked this up?

[beckers2008] 26/10/2021 17:57

ASTRAZENECA : Deutsche Bank reiterates its Buy rating
10/26/2021 | 11:48am BST

In a research note published by Emmanuel Papadakis, Deutsche Bank advises its customers to buy the stock. The target price remains unchanged at GBX 105.00.

[beckers2008] 21/10/2021 14:02

Bit late on this one but as well as J.P. Morgan, )thanks philanderer) Credit Suisse have reaffirmed.

ASTRAZENECA : Credit Suisse remains its Buy rating
10/20/2021 | 03:00pm BST

In his latest research note, analyst Dominic Lunn confirms his positive recommendation. The broker Credit Suisse is keeping its Buy rating. The target price continues to be set at GBX 9000.

[philanderer] 21/10/2021 13:51

J.P.Morgan keeps AstraZeneca as 'top pick' on growth outlook, undervaluation


(Sharecast News) - AstraZeneca's growth outlook is the best in its sector and was not yet reflected in its share price, analysts at JP Morgan said following a 'deep dive' into the drug maker's financials.
Hence their decision to keep the shares as their 'top pick' in the sector.

In local currency terms, the broker estimated that the company's core earnings per share were set to grow by 33%, 27% and 23% between 2021-23 - excluding its Covid-19 vaccine.

Subsequently, EPS was seen growing at a compound annual rate of growth of 9% over 2023-26.

Furthermore, Astra was only trading on 14.5 times' its estimated core EPS for 2023, against its sector trading on 16.5

Yet the expected rate of growth in the drugmaker's core EPS across 2023-26 in compound annual terms was expected to be four percentage points higher thanks to its comparatively young on-market portfolio and deep late stage pipeline.

"Given our forecast for a strong growth outlook, and the compelling valuation, we remain Overweight, with Astra remaining a top pick in the sector."

[arja] 19/10/2021 08:21

nothing helping the share price at present as it drifts slowly down .

[grupo guitarlumber] 15/10/2021 13:15

AstraZeneca said results from its Himalaya Phase III trial showed a single dose of tremelimumab added to Imfinzi significantly improved overall survival in liver cancer.

The trial met the primary objective of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks versus sorafenib for patients with unresectable hepatocellular carcinoma, or HCC, the company said. Imfinzi monotherapy met the overall survival endpoint of non-inferiority versus sorafenib, AstraZeneca said.

Imfinzi and tremelimumab were granted orphan drug designations in the U.S. for the treatment of HCC in 2020. Tremelimumab was also granted orphan designation in the European Union in HCC in 2020.



Write to Michael Dabaie at [e-mail]



(END) Dow Jones Newswires

October 15, 2021 07:50 ET (11:50 GMT)

[arja] 15/10/2021 11:21

rocketing US indices have no affect on AZN in last few days as it struggles to hold any mini intra day rally . Needs s blockbuster good news announcement I guess !

[arja] 12/10/2021 15:56

anyone know if lead market for this stock is USA as a bit tricky to establish
which follows which after 2.30pm ? I suspect US rules as always

[arja] 12/10/2021 14:49

lockkeeper ,
true but who is the crank ? not yourself ?
Just noticed AZN was much higher early today and not sure why as no bullish news I THINK !

[beckers2008] 11/10/2021 13:46

AstraZeneca : Deutsche Bank Boosts AstraZeneca's PT, Keeps PT
10/11/2021 | 01:23pm BST

(MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) on Monday raised its price target on AstraZeneca (AZN.L, AZN.ST) to 105 pounds sterling ($143.19) from 102 pounds and maintained its buy rating.

The Anglo-Swedish pharmaceutical company's shares increased marginally on Monday midday.